Cargando…

Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study

BACKGROUND: Coronavirus disease 2019 (COVID-19) has strained healthcare systems with patient hospitalizations and deaths. Anti-spike monoclonal antibodies, including bamlanivimab, have demonstrated reduction in hospitalization rates in clinical trials, yet real-world evidence is lacking. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Rebecca N, Wu, En-Ling, Stosor, Valentina, Moore, William J, Achenbach, Chad, Ison, Michael G, Angarone, Michael P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083260/ https://www.ncbi.nlm.nih.gov/pubmed/33846730 http://dx.doi.org/10.1093/cid/ciab305

Ejemplares similares

Disparities in COVID-19 Monoclonal Antibody Delivery: a Retrospective Cohort Study
por: Wu, En-Ling, et al.
Publicado: (2022)

Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Bariola, J Ryan, et al.
Publicado: (2021)

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial
por: Chen, Peter, et al.
Publicado: (2022)

215a. Use of Viracor Cytomegalovirus T-Cell Immunity Panel (TCIP) to Predict the Risk of Recurrent Cytomegalovirus Infection in Solid Transplant Patients and Guide Appropriate Management
por: Vysniauskaite, Indre, et al.
Publicado: (2022)

Real World Utilization of Bamlanivimab at a Rural Community Hospital
por: Leavitt, Rachael, et al.
Publicado: (2021)

Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process
por: Rubin, Emily B, et al.
Publicado: (2021)

1164. Epidemiology of Cryptococcal Infections in Non-HIV Patients: A 20-year Single Center Experience
por: Kumar, Rebecca Nirmal, et al.
Publicado: (2020)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

1129. Targeted Voriconazole Prophylaxis in Heart Transplantation Recipients
por: Lin, Michael, et al.
Publicado: (2018)

A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
por: Dougan, Michael, et al.
Publicado: (2021)

The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
por: Corwin, Douglas S, et al.
Publicado: (2021)

Bamlanivimab infusion experience at one academic emergency department
por: Yoo, Michael J., et al.
Publicado: (2022)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China: A Retrospective Cohort Study
por: Tang, Lin, et al.
Publicado: (2023)

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region
por: Vena, Antonio, et al.
Publicado: (2021)

Bamlanivimab/immunosuppressants: Headache/fatigue following off-label treatment and Coronavirus disease-2019: 18 case reports
Publicado: (2022)

Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019
por: Tziolos, Nikolaos, et al.
Publicado: (2021)

Dying at Home Due to Coronavirus Disease 2019
por: Edwards, Jessie K, et al.
Publicado: (2022)

Propensity-Score Matched Analysis of the Effectiveness of Baricitinib in Patients With Coronavirus Disease 2019 (COVID-19) Using Nationwide Real-World Data: An Observational Matched Cohort Study From the Japan COVID-19 Task Force
por: Tanaka, Hiromu, et al.
Publicado: (2023)

A Qualitative Study of the Real-world Experiences of Infectious Diseases Fellows Regarding Antibiotic Stewardship
por: Morgan, Jake R, et al.
Publicado: (2018)

The Clinical and Radiological Manifestations in Coronavirus Disease 2019 With Negative Nucleic Acid Results
por: Lang, Guanjing, et al.
Publicado: (2020)

Coronavirus Disease 2019–Associated Invasive Fungal Infection
por: Baddley, John W, et al.
Publicado: (2021)

Impact of Procalcitonin-Guided Antibiotic Management on Antibiotic Exposure and Outcomes: Real-world Evidence
por: Broyles, Michael R
Publicado: (2017)

Risk of Coronavirus Disease 2019–Associated Pulmonary Aspergillosis Based on Corticosteroid Duration in Intensive Care Patients
por: Shah, Meera, et al.
Publicado: (2023)

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
por: Alosaimy, Sara, et al.
Publicado: (2021)

Real-World Experience With Higher-Than-Recommended Doses of Lamivudine in Patients With Varying Degrees of Renal Impairment
por: Fischetti, Briann, et al.
Publicado: (2018)

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
por: Hengel, Richard L, et al.
Publicado: (2020)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021)

Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus
por: Ho, Hsi-en, et al.
Publicado: (2020)

Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019
por: Mandell, Lionel A, et al.
Publicado: (2022)

Coronavirus Disease 2019-Associated Pulmonary Aspergillosis: Reframing the Debate
por: Clancy, Cornelius J, et al.
Publicado: (2022)

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
por: Bonny, Tania S, et al.
Publicado: (2020)

Coronavirus Disease 2019 Severity and Risk of Subsequent Cardiovascular Events
por: Wiemken, Timothy L, et al.
Publicado: (2022)

Contribution of Coronavirus-Specific Immunoglobulin G Responses to Complement Overactivation in Patients with Severe Coronavirus Disease 2019( )
por: Castanha, Priscila M S, et al.
Publicado: (2022)

Clinical and Pregnancy Outcomes of Coronavirus Disease 2019 Among Hospitalized Pregnant Women in the United States
por: Ackerman, Christina M, et al.
Publicado: (2021)

Remdesivir retreatment: another unproven intervention for COVID-19
por: Al-Heeti, Omar, et al.
Publicado: (2022)

The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections
por: Redell, Mark, et al.
Publicado: (2019)

Impact of Vaccination With the SCB-2019 Coronavirus Disease 2019 Vaccine on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Household Contact Study in the Philippines
por: Tadesse, Birkneh Tilahun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6k1mbe9mgrkvgc7gderogbpd73